Probiotic Supplements on Oncology Patients’ Treatment-Related Side Effects: A Systematic Review of Randomized Controlled Trials

Rodriguez‐Arrastia, Miguel; Martinez-Ortigosa, Adrian; Rueda‐Ruzafa, Lola; Ayora, Ana Folch; Ropero‐Padilla, Carmen

doi:10.3390/ijerph18084265

Cited by 40 publications

(26 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Table 4 illustrates examples from human clinical trials [ 131 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 163 , 164 , 165 , 166 , 167 , 168 , 169 , 170 , 171 , 172 , 173 , 174 , 175 , 176 , 177 , 178 , 179 , 180 , 181 , 182 , 183 ]. Not surprisingly, the best outcomes occur when there is a clear understanding of the specific microbes, genes, metabolic changes, and installation conditions that are needed to support microbiome-driven physiological benefits.…”

Section: Probiotics Prebiotics and Targeted Rebiosis: Clinical And Preclinical Examplesmentioning

confidence: 99%

Microbiome First Medicine in Health and Safety

Dietert

2021

Biomedicines

View full text Add to dashboard Cite

Microbiome First Medicine is a suggested 21st century healthcare paradigm that prioritizes the entire human, the human superorganism, beginning with the microbiome. To date, much of medicine has protected and treated patients as if they were a single species. This has resulted in unintended damage to the microbiome and an epidemic of chronic disorders [e.g., noncommunicable diseases and conditions (NCDs)]. Along with NCDs came loss of colonization resistance, increased susceptibility to infectious diseases, and increasing multimorbidity and polypharmacy over the life course. To move toward sustainable healthcare, the human microbiome needs to be front and center. This paper presents microbiome-human physiology from the view of systems biology regulation. It also details the ongoing NCD epidemic including the role of existing drugs and other factors that damage the human microbiome. Examples are provided for two entryway NCDs, asthma and obesity, regarding their extensive network of comorbid NCDs. Finally, the challenges of ensuring safety for the microbiome are detailed. Under Microbiome-First Medicine and considering the importance of keystone bacteria and critical windows of development, changes in even a few microbiota-prioritized medical decisions could make a significant difference in health across the life course.

show abstract

Section: Probiotics Prebiotics and Targeted Rebiosis: Clinical And Preclinical Examplesmentioning

confidence: 99%

Microbiome First Medicine in Health and Safety

Dietert

2021

Biomedicines

View full text Add to dashboard Cite

show abstract

“…We discussed results from studies showing that Lactobacilli and Bifidobacterium affect the occurrence and progression of CRC in animal models (89)(90)(91). Some probiotics can help to not only enhance the effects of anti-cancer therapeutic agents but also alleviate the side effects caused by conventional cancer treatments (108). However, these probiotics also have the potential to act as opportunistic pathogens that can easily penetrate the intestinal barrier and immune environment after weakening by intestinal tumors (109).…”

Section: Microbiome Modulation For Colon Cancer Treatmentmentioning

confidence: 99%

Potential Role of the Gut Microbiome In Colorectal Cancer Progression

Kim

Lee

2022

Front. Immunol.

View full text Add to dashboard Cite

An increasing number of studies have revealed that the progression of colorectal cancer (CRC) is related to gut microbiome composition. Under normal conditions, the gut microbiome acts as a barrier to other pathogens or infections in the intestine and modulates inflammation by affecting the host immune system. These gut microbiota are not only related to the intestinal inflammation associated with tumorigenesis but also modulation of the anti-cancer immune response. Thus, they are associated with tumor progression and anti-cancer treatment efficacy. Studies have shown that the gut microbiota can be used as biomarkers to predict the effect of immunotherapy and improve the efficacy of immunotherapy in treating CRC through modulation. In this review, we discuss the role of the gut microbiome as revealed by recent studies of the growth and progression of CRC along with its synergistic effect with anti-cancer treatment modalities.

show abstract

“…To this end, unfavorable microbial signatures should be ablated, and beneficial communities could be enhanced. Microbiome modulation in order to improve anticancer therapy may be achieved via FMT, pre-/pro-/post- and antibiotics, dietary modifications, and phage therapy approaches in order to enhance anticancer therapy [ 23 , 95 , 118 , 119 , 120 , 121 ]. The latter represents a potent option for targeting specific bacteria with minimum off-target effects; this is an almost impossible challenge with antibiotic treatment, which usually eradicates a broad spectrum of microbiota.…”

Section: Influence Of the Microbiome On Treatment And Prognosis Of Pdacmentioning

confidence: 99%

The Microbiome in PDAC—Vantage Point for Future Therapies?

Pfisterer

Heuer²,

Dang

et al. 2022

Cancers

View full text Add to dashboard Cite

Microorganisms have been increasingly implicated in the pathogenesis of malignant diseases, potentially affecting different hallmarks of cancer. Despite the fact that we have recently gained tremendous insight into the existence and interaction of the microbiome with neoplastic cells, we are only beginning to understand and exploit this knowledge for the treatment of human malignancies. Pancreatic ductal adenocarcinoma (PDAC) is an aggressive solid tumor with limited therapeutic options and a poor long-term survival. Recent data have revealed fascinating insights into the role of the tumoral microbiome in PDAC, with profound implications for survival and potentially therapeutic outcomes. In this review, we outline the current scientific knowledge about the clinical and translational role of the microbiome in PDAC. We describe the microbial compositions in healthy and tumoral pancreatic tissue and point out four major aspects of the microbiome in PDAC: pathogenesis, diagnosis, treatment, and prognosis. However, caution must be drawn to inherent pitfalls in analyzing the intratumoral microbiome. Among others, contamination with environmental microbes is one of the major challenges. To this end, we discuss different decontamination approaches that are crucial for clinicians and scientists alike to foster applicability and physiological relevance in this translational field. Without a definition of an exact and reproducible intratumoral microbial composition, the exploitation of the microbiome as a diagnostic or therapeutic tool remains theoretical.

show abstract

Probiotic Supplements on Oncology Patients’ Treatment-Related Side Effects: A Systematic Review of Randomized Controlled Trials

Cited by 40 publications

References 60 publications

Microbiome First Medicine in Health and Safety

Microbiome First Medicine in Health and Safety

Potential Role of the Gut Microbiome In Colorectal Cancer Progression

The Microbiome in PDAC—Vantage Point for Future Therapies?

Contact Info

Product

Resources

About